Cargando…

Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination

Background: Non-small-cell lung cancer (NSCLC) with STK11 mutation showed primary resistance to immune checkpoint inhibitors (ICIs). The glucose-lowering drug metformin exerted anti-cancer effect and enhanced efficacy of chemotherapy in NSCLC with KRAS/STK11 co-mutation, yet it is unknown whether me...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiguo, Lu, Conghua, Zhang, Kejun, Lin, Caiyu, Wu, Fang, Tang, Xiaolin, Wu, Di, Dou, Yuanyao, Han, Rui, Wang, Yubo, Hou, Chao, Ouyang, Qin, Feng, Mingxia, He, Yong, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905189/
https://www.ncbi.nlm.nih.gov/pubmed/35281267
http://dx.doi.org/10.3389/fmolb.2022.780200
_version_ 1784665135148695552
author Wang, Zhiguo
Lu, Conghua
Zhang, Kejun
Lin, Caiyu
Wu, Fang
Tang, Xiaolin
Wu, Di
Dou, Yuanyao
Han, Rui
Wang, Yubo
Hou, Chao
Ouyang, Qin
Feng, Mingxia
He, Yong
Li, Li
author_facet Wang, Zhiguo
Lu, Conghua
Zhang, Kejun
Lin, Caiyu
Wu, Fang
Tang, Xiaolin
Wu, Di
Dou, Yuanyao
Han, Rui
Wang, Yubo
Hou, Chao
Ouyang, Qin
Feng, Mingxia
He, Yong
Li, Li
author_sort Wang, Zhiguo
collection PubMed
description Background: Non-small-cell lung cancer (NSCLC) with STK11 mutation showed primary resistance to immune checkpoint inhibitors (ICIs). The glucose-lowering drug metformin exerted anti-cancer effect and enhanced efficacy of chemotherapy in NSCLC with KRAS/STK11 co-mutation, yet it is unknown whether metformin may enhance ICI efficacy in STK11 mutant NSCLC. Methods: We studied the impact of metformin on ICI efficacy in STK11 mutant NSCLC in vitro and in vivo using colony formation assay, cell viability assay, Ki67 staining, ELISA, CRISPR/Cas9-mediated knockout, and animal experiments. Results: Through colony formation assay, Ki67 incorporation assay, and CCK-8 assay, we found that metformin significantly enhanced the killing of H460 cells and A549 cells by T cells. In NOD-SCID xenografts, metformin in combination with PD-1 inhibitor pembrolizumab effectively decreased tumor growth and increased infiltration of CD8(+) T cells. Metformin enhanced stabilization of STING and activation of its downstream signaling pathway. siRNA-mediated knockdown of STING abolished the effect of metformin on T cell-mediated killing of tumor cells. Next, we found that CRISPR/Cas9-mediated knockout of the scaffold protein AXIN-1 abolished the effect of metformin on T cell-mediated killing and STING stabilization. Immunoprecipitation and confocal macroscopy revealed that metformin enhanced the interaction and colocalization between AXIN-1 and STING. Protein-protein interaction modeling indicated that AXIN-1 may directly bind to STING at its K150 site. Next, we found that metformin decreased K48-linked ubiquitination of STING and inhibited the interaction of E3-ligand RNF5 and STING. Moreover, in AXIN-1 ( −/− ) H460 cells, metformin failed to alter the interaction of RNF5 and STING. Conclusion: Metformin combining PD-1 inhibitor enhanced anti-tumor efficacy in STK11 mutant lung cancer through inhibition of RNF5-mediated K48-linked ubiquitination of STING, which was dependent on AXIN-1.
format Online
Article
Text
id pubmed-8905189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89051892022-03-10 Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination Wang, Zhiguo Lu, Conghua Zhang, Kejun Lin, Caiyu Wu, Fang Tang, Xiaolin Wu, Di Dou, Yuanyao Han, Rui Wang, Yubo Hou, Chao Ouyang, Qin Feng, Mingxia He, Yong Li, Li Front Mol Biosci Molecular Biosciences Background: Non-small-cell lung cancer (NSCLC) with STK11 mutation showed primary resistance to immune checkpoint inhibitors (ICIs). The glucose-lowering drug metformin exerted anti-cancer effect and enhanced efficacy of chemotherapy in NSCLC with KRAS/STK11 co-mutation, yet it is unknown whether metformin may enhance ICI efficacy in STK11 mutant NSCLC. Methods: We studied the impact of metformin on ICI efficacy in STK11 mutant NSCLC in vitro and in vivo using colony formation assay, cell viability assay, Ki67 staining, ELISA, CRISPR/Cas9-mediated knockout, and animal experiments. Results: Through colony formation assay, Ki67 incorporation assay, and CCK-8 assay, we found that metformin significantly enhanced the killing of H460 cells and A549 cells by T cells. In NOD-SCID xenografts, metformin in combination with PD-1 inhibitor pembrolizumab effectively decreased tumor growth and increased infiltration of CD8(+) T cells. Metformin enhanced stabilization of STING and activation of its downstream signaling pathway. siRNA-mediated knockdown of STING abolished the effect of metformin on T cell-mediated killing of tumor cells. Next, we found that CRISPR/Cas9-mediated knockout of the scaffold protein AXIN-1 abolished the effect of metformin on T cell-mediated killing and STING stabilization. Immunoprecipitation and confocal macroscopy revealed that metformin enhanced the interaction and colocalization between AXIN-1 and STING. Protein-protein interaction modeling indicated that AXIN-1 may directly bind to STING at its K150 site. Next, we found that metformin decreased K48-linked ubiquitination of STING and inhibited the interaction of E3-ligand RNF5 and STING. Moreover, in AXIN-1 ( −/− ) H460 cells, metformin failed to alter the interaction of RNF5 and STING. Conclusion: Metformin combining PD-1 inhibitor enhanced anti-tumor efficacy in STK11 mutant lung cancer through inhibition of RNF5-mediated K48-linked ubiquitination of STING, which was dependent on AXIN-1. Frontiers Media S.A. 2022-02-23 /pmc/articles/PMC8905189/ /pubmed/35281267 http://dx.doi.org/10.3389/fmolb.2022.780200 Text en Copyright © 2022 Wang, Lu, Zhang, Lin, Wu, Tang, Wu, Dou, Han, Wang, Hou, Ouyang, Feng, He and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Wang, Zhiguo
Lu, Conghua
Zhang, Kejun
Lin, Caiyu
Wu, Fang
Tang, Xiaolin
Wu, Di
Dou, Yuanyao
Han, Rui
Wang, Yubo
Hou, Chao
Ouyang, Qin
Feng, Mingxia
He, Yong
Li, Li
Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
title Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
title_full Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
title_fullStr Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
title_full_unstemmed Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
title_short Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
title_sort metformin combining pd-1 inhibitor enhanced anti-tumor efficacy in stk11 mutant lung cancer through axin-1-dependent inhibition of sting ubiquitination
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905189/
https://www.ncbi.nlm.nih.gov/pubmed/35281267
http://dx.doi.org/10.3389/fmolb.2022.780200
work_keys_str_mv AT wangzhiguo metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT luconghua metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT zhangkejun metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT lincaiyu metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT wufang metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT tangxiaolin metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT wudi metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT douyuanyao metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT hanrui metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT wangyubo metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT houchao metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT ouyangqin metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT fengmingxia metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT heyong metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination
AT lili metformincombiningpd1inhibitorenhancedantitumorefficacyinstk11mutantlungcancerthroughaxin1dependentinhibitionofstingubiquitination